Literature DB >> 33070425

Relationship between coffee consumption, sleep duration and smoking status with elastographic parameters of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements.

Ivana Mikolasevic1,2,3, Viktor Domislovic4, Tajana Filipec Kanizaj2,5, Delfa Radic-Kristo5,6, Zeljko Krznaric4,5, Tamara Milovanovic7, Toni Juric3, Mia Klapan3, Nadija Skenderevic2, Bozena Delija3, Tajana Stevanovic3, Ana Mijic3, Andjela Lukic3, Davor Stimac1,3.   

Abstract

AIM: our aim was to explore the association between life habits and the controlled attenuation parameter (CAP) and liver stiffness measurements (LSM) as the surrogate markers of liver steatosis and fibrosis in a large cohort of non-alcoholic fatty liver disease (NAFLD) patients.
METHODS: In this prospective, cross-sectional study we had analysed 1998 patients with diagnosed NAFLD. Sleeping duration was categorised in three groups: short (S) (<6 hours), moderate (M) (6-8 hours) and long (L) (>8 hours) sleep duration. Coffee drinking was categorized into no (0), moderate (1-2) and frequent (≥3) consumption (in cups/day). Smoking was categorised as yes versus no.
RESULTS: Frequent coffee consumers had the lowest prevalence of obesity, hypertension, dyslipidaemia and diabetes. Furthermore, coffee non-consumers had highest values of hepatic enzymes, CAP and LSM. Moderate sleep duration was associated with lower values of CAP and LSM. Coffee consumption was associated with lower CAP in all the multivariate models (CAP unadjusted and model 1, 2 and 3), with largest effect in most frequent coffee consumers (≥3, model 3). Also, most frequent coffee consumers were associated with lower LSM in unadjusted model, model 1 and 2, while this was not the case for model 3 and those who consumed 1-2 cups of coffee per day. Reduced sleeping was confirmed as risk factor for elevated CAP in most of the models (unadjusted and model 1 and 2). Also, negative association of LSM was also confirmed in unadjusted model and model 2. Patients which slept 6-8 hours per day were mostly associated with lower CAP and LSM. Smoking status was not associated with CAP or LSM values.
CONCLUSION: Coffee consumption has beneficial effect on CAP and LSM and this effect is dose dependent since and independent of a variety of relevant confounders. We have shown that moderate sleep duration has also beneficial effect on CAP and LSM.
© 2020 John Wiley & Sons Ltd.

Entities:  

Year:  2020        PMID: 33070425     DOI: 10.1111/ijcp.13770

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  4 in total

1.  Investigating the Association Between Seven Sleep Traits and Nonalcoholic Fatty Liver Disease: Observational and Mendelian Randomization Study.

Authors:  Hong Fan; Zhenqiu Liu; Xin Zhang; Huangbo Yuan; Xiaolan Zhao; Renjia Zhao; Tingting Shi; Sheng Wu; Yiyun Xu; Chen Suo; Xingdong Chen; Tiejun Zhang
Journal:  Front Genet       Date:  2022-05-17       Impact factor: 4.772

Review 2.  Plant-Based Foods and Their Bioactive Compounds on Fatty Liver Disease: Effects, Mechanisms, and Clinical Application.

Authors:  Hang-Yu Li; Ren-You Gan; Ao Shang; Qian-Qian Mao; Quan-Cai Sun; Ding-Tao Wu; Fang Geng; Xiao-Qin He; Hua-Bin Li
Journal:  Oxid Med Cell Longev       Date:  2021-03-01       Impact factor: 6.543

Review 3.  Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis.

Authors:  Chayanis Kositamongkol; Sukrit Kanchanasurakit; Chiraphong Auttamalang; Nutkamon Inchai; Thanatchaporn Kabkaew; Sarunporn Kitpark; Nathorn Chaiyakunapruk; Acharaporn Duangjai; Surasak Saokaew; Pochamana Phisalprapa
Journal:  Front Pharmacol       Date:  2021-12-13       Impact factor: 5.810

Review 4.  It Is High Time Physicians Thought of Natural Products for Alleviating NAFLD. Is There Sufficient Evidence to Use Them?

Authors:  Giovanni Tarantino; Clara Balsano; Silvano Junior Santini; Giovanni Brienza; Irma Clemente; Benedetta Cosimini; Gaia Sinatti
Journal:  Int J Mol Sci       Date:  2021-12-14       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.